single protocol
Survodutide (10 mg Vial) Dosage Protocol
Survodutide dosage chart for the 10 mg Vial: typical dose 600 mcg–6 mg weekly, reconstitution to 5 mg/mL, and protocol. For research use only.
Survodutide Dosage Chart
Survodutide is dosed at 600 mcg–6 mg weekly via subcutaneous injection in educational protocols. A 10 mg vial reconstituted with bacteriostatic water yields about 5 mg/mL. This information is for research and educational use only.
- Reconstitute: Add 2.0 mL bacteriostatic water → 5 mg/mL (5000 mcg/mL) concentration.
- Typical weekly range: 0.6–6.0 mg once weekly (gradual titration over 10–12 weeks).
- Easy measuring: At 5 mg/mL, 1 unit = 0.01 mL = 50 mcg on a U‑100 insulin syringe.
- Storage: Lyophilized: freeze at ≤−20 °C (≤−4 °F); after reconstitution, refrigerate at 2–8 °C (35.6–46.4 °F); protect from light.
Survodutide (BI 456906) is an investigational dual GLP‑1/glucagon receptor agonist under development for obesity and metabolic liver disease[1][2]. In phase 2 trials, once‑weekly subcutaneous dosing (0.6–4.8 mg) produced dose‑dependent weight loss of 12.5–14.9% versus placebo over 46 weeks[1]. This educational protocol presents a once‑weekly subcutaneous titration approach using a practical dilution for clear insulin‑syringe measurements.
Related research: For distinct compound, component, or formulation evidence and safety context, read Mazdutide Peptide: Benefits, Uses, Side Effects, Dosage, and Research. These links are comparisons only; the compounds and formulations should not be treated as interchangeable.
Dosing & Reconstitution Guide
Educational guide for reconstitution and weekly dosing
Standard / Gradual Titration (2 mL = 5 mg/mL)
Route & Frequency: Subcutaneous injection once weekly (all clinical trials used weekly dosing)[1][2].
| Week | Weekly Dose (mg) | Weekly Dose (mcg) | Units (mL) |
|---|---|---|---|
| Weeks 1–2 | 0.6 mg | 600 mcg | 12 units (0.12 mL) |
| Weeks 3–4 | 1.2 mg | 1200 mcg | 24 units (0.24 mL) |
| Weeks 5–6 | 1.8 mg | 1800 mcg | 36 units (0.36 mL) |
| Weeks 7–8 | 2.4 mg | 2400 mcg | 48 units (0.48 mL) |
| Weeks 9–10 | 3.6 mg | 3600 mcg | 72 units (0.72 mL) |
| Weeks 11–12 | 4.8 mg | 4800 mcg | 96 units (0.96 mL) |
| Week 13+ | 6.0 mg | 6000 mcg | 120 units (1.20 mL)* |
*Note: The 6.0 mg maintenance dose (120 units / 1.20 mL) exceeds a standard 100‑unit (1 mL) insulin syringe. Use a 1 mL or 3 mL Luer‑lock syringe with appropriate needle, or administer as two separate injections.
Reconstitution Steps
- Draw 2.0 mL bacteriostatic water with a sterile syringe.
- Inject slowly down the vial wall; avoid foaming.
- Gently swirl/roll until dissolved (do not shake).
- Label and refrigerate at 2–8 °C (35.6–46.4 °F), protected from light.